Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 03 Jan 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary)
Indications Non-small cell lung cancer
Focus Pharmacodynamics
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

14 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.
14 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Mar 2017.
25 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight